JP2016510989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510989A5 JP2016510989A5 JP2015562528A JP2015562528A JP2016510989A5 JP 2016510989 A5 JP2016510989 A5 JP 2016510989A5 JP 2015562528 A JP2015562528 A JP 2015562528A JP 2015562528 A JP2015562528 A JP 2015562528A JP 2016510989 A5 JP2016510989 A5 JP 2016510989A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- administration
- poxvirus
- nucleic acid
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/055409 WO2014139587A1 (en) | 2013-03-15 | 2013-03-15 | Improved poxviral vaccines |
| EPPCT/EP2013/055409 | 2013-03-15 | ||
| PCT/IB2014/059802 WO2014141176A1 (en) | 2013-03-15 | 2014-03-14 | Improved poxviral vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510989A JP2016510989A (ja) | 2016-04-14 |
| JP2016510989A5 true JP2016510989A5 (https=) | 2017-04-13 |
| JP6702725B2 JP6702725B2 (ja) | 2020-06-03 |
Family
ID=47882194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562528A Expired - Fee Related JP6702725B2 (ja) | 2013-03-15 | 2014-03-14 | 改良されたポックスウイルスワクチン |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20160000904A1 (https=) |
| EP (1) | EP2968493B1 (https=) |
| JP (1) | JP6702725B2 (https=) |
| CN (2) | CN109182378A (https=) |
| BE (1) | BE1021192B1 (https=) |
| BR (1) | BR112015023524B1 (https=) |
| CA (1) | CA2907026A1 (https=) |
| CY (1) | CY1120740T1 (https=) |
| DK (1) | DK2968493T3 (https=) |
| ES (1) | ES2685922T3 (https=) |
| HR (1) | HRP20181376T1 (https=) |
| HU (1) | HUE040189T2 (https=) |
| LT (1) | LT2968493T (https=) |
| PL (1) | PL2968493T3 (https=) |
| PT (1) | PT2968493T (https=) |
| SI (1) | SI2968493T1 (https=) |
| WO (2) | WO2014139587A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139587A1 (en) | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
| US10576143B2 (en) | 2013-03-15 | 2020-03-03 | Glaxosmithkline Biologicals Sa | Poxviral vaccines |
| GB201321384D0 (en) * | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
| WO2017025782A1 (en) * | 2014-09-17 | 2017-02-16 | Glaxosmithkline Biologicals Sa | Improved poxviral vaccines |
| WO2016184822A1 (en) | 2015-05-15 | 2016-11-24 | Curevac Ag | Prime-boost regimens involving administration of at least one mrna construct |
| EP3504230A1 (en) | 2016-08-23 | 2019-07-03 | GlaxoSmithKline Biologicals SA | Fusion peptides with antigens linked to short fragments of invariant chain (cd74) |
| GB201704417D0 (en) | 2017-03-20 | 2017-05-03 | Univ Copenhagen | Improved li vaccine adjuvant |
| JP7298926B2 (ja) * | 2017-07-12 | 2023-06-27 | ノイスコム アーゲー | 癌の治療のためのネオアンチゲンワクチン組成物 |
| GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
| GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
| GB201812647D0 (en) | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
| EP3833382A1 (en) | 2018-08-07 | 2021-06-16 | GlaxoSmithKline Biologicals S.A. | Processes and vaccines |
| EP3897846A1 (en) * | 2018-12-21 | 2021-10-27 | GlaxoSmithKline Biologicals SA | Methods of inducing an immune response |
| CA3132601A1 (en) | 2019-03-05 | 2020-09-10 | Glaxosmithkline Biologicals Sa | Hepatitis b immunisation regimen and compositions |
| CN111057716B (zh) * | 2019-07-27 | 2022-04-15 | 中国人民解放军军事科学院军事医学研究院 | 用于包装重组人4型腺病毒的单质粒载体系统及其应用 |
| WO2024133160A1 (en) | 2022-12-19 | 2024-06-27 | Glaxosmithkline Biologicals Sa | Hepatitis b compositions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1272179B (it) | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
| IT1278077B1 (it) | 1995-05-25 | 1997-11-17 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal |
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| US7598362B2 (en) | 2001-10-11 | 2009-10-06 | Merck & Co., Inc. | Hepatitis C virus vaccine |
| ATE315660T1 (de) * | 2002-05-16 | 2006-02-15 | Bavarian Nordic As | Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva) |
| DE602005017743D1 (de) | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| EP1957528B1 (en) | 2005-11-30 | 2012-11-07 | University of Copenhagen | A nucleotide vaccine |
| EP3552622A3 (en) | 2008-11-21 | 2019-12-04 | Københavns Universitet (University Of Copenhagen) | Priming of an immune response |
| PL2391638T3 (pl) | 2009-02-02 | 2018-11-30 | Glaxosmithkline Biologicals Sa | Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania |
| WO2014139587A1 (en) | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
| US10576143B2 (en) * | 2013-03-15 | 2020-03-03 | Glaxosmithkline Biologicals Sa | Poxviral vaccines |
| GB201321384D0 (en) | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
| EP3504230A1 (en) | 2016-08-23 | 2019-07-03 | GlaxoSmithKline Biologicals SA | Fusion peptides with antigens linked to short fragments of invariant chain (cd74) |
-
2013
- 2013-03-15 WO PCT/EP2013/055409 patent/WO2014139587A1/en not_active Ceased
-
2014
- 2014-03-14 LT LTEP14723475.1T patent/LT2968493T/lt unknown
- 2014-03-14 BR BR112015023524-7A patent/BR112015023524B1/pt not_active IP Right Cessation
- 2014-03-14 WO PCT/IB2014/059802 patent/WO2014141176A1/en not_active Ceased
- 2014-03-14 CN CN201811100700.2A patent/CN109182378A/zh active Pending
- 2014-03-14 HR HRP20181376TT patent/HRP20181376T1/hr unknown
- 2014-03-14 DK DK14723475.1T patent/DK2968493T3/en active
- 2014-03-14 HU HUE14723475A patent/HUE040189T2/hu unknown
- 2014-03-14 SI SI201430827T patent/SI2968493T1/sl unknown
- 2014-03-14 PL PL14723475T patent/PL2968493T3/pl unknown
- 2014-03-14 CA CA2907026A patent/CA2907026A1/en active Pending
- 2014-03-14 BE BE2014/0166A patent/BE1021192B1/fr not_active IP Right Cessation
- 2014-03-14 CN CN201480015680.2A patent/CN105307674A/zh active Pending
- 2014-03-14 PT PT14723475T patent/PT2968493T/pt unknown
- 2014-03-14 ES ES14723475.1T patent/ES2685922T3/es active Active
- 2014-03-14 US US14/770,510 patent/US20160000904A1/en not_active Abandoned
- 2014-03-14 JP JP2015562528A patent/JP6702725B2/ja not_active Expired - Fee Related
- 2014-03-14 EP EP14723475.1A patent/EP2968493B1/en active Active
-
2017
- 2017-12-20 US US15/848,100 patent/US10588961B2/en active Active
-
2018
- 2018-08-14 CY CY181100859T patent/CY1120740T1/el unknown
-
2020
- 2020-02-05 US US16/782,268 patent/US11278614B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510989A5 (https=) | ||
| ES2800623T3 (es) | Promotor PR13.5 para respuestas contundentes de células T y anticuerpos | |
| Herbert et al. | Recombinant adenovirus expressing the haemagglutinin of peste des petits ruminants virus (PPRV) protects goats against challenge with pathogenic virus; a DIVA vaccine for PPR | |
| Verardi et al. | A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication | |
| EP1616954B1 (en) | Methods and reagents for vaccination which generate a CD8+ Tcell immune response against hepatitis B or C | |
| Schneider et al. | Induction of CD8+ T cells using heterologous prime‐boost immunisation strategies | |
| MX2022009962A (es) | Vacunas y usos de la mismas para inducir una respuesta inmunitaria al sars-cov-2. | |
| JP2014503206A5 (https=) | ||
| JP2015533841A5 (https=) | ||
| AU2002347317B2 (en) | Vaccine | |
| US20160304582A1 (en) | Molecular adjuvant | |
| JP2020516264A5 (https=) | ||
| MX2017002791A (es) | Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante. | |
| JP2013507907A5 (https=) | ||
| CA3067405A1 (en) | Personalized vaccine comprising a recombinant poxvirus expressing a fusioin of nepopeptides | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| RU2019107976A (ru) | Композиция вакцины | |
| JP6851364B2 (ja) | ポックスウイルスにおける発現を増強するためのプロモーター | |
| JP2016510989A (ja) | 改良されたポックスウイルスワクチン | |
| JP2012515557A5 (https=) | ||
| MX2017016273A (es) | Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante. | |
| JP2017527568A (ja) | フィロウイルス感染に対する防御免疫の誘導を目的とする方法及び組成物 | |
| JP2017503479A (ja) | ポックスウイルスベクターを用いて増強された免疫応答を誘導するための組成物及び方法ベクター | |
| JP2018521651A5 (https=) | ||
| JP2016074727A5 (https=) |